84 results on '"Wyde PR"'
Search Results
2. Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice.
- Author
-
Haidari M, Wyde PR, Litovsky S, Vela D, Ali M, Casscells SW, and Madjid M
- Subjects
- Animals, Arteries virology, Inflammation virology, Mice, Atherosclerosis virology, Orthomyxoviridae pathogenicity
- Abstract
Objective: Influenza can trigger heart attacks, and vaccination against influenza reduces the risk of cardiovascular events. Currently, it is believed that influenza virus in general does not disseminate to extra-pulmonary tissues. We assessed the vascular effects of influenza infection and whether the virus can directly infect atherosclerotic arteries in mice., Methods/results: We intranasally infected 4 different types of mice--atherosclerotic apo E-deficient (our primary model), LDL receptor knockout, C57BL/6, and outbred Swiss--with influenza A/HK (H3/N2) virus. On day 7 after infection, we cultured viable virus from lung, aorta, and heart tissue, but not from the blood of apo E-deficient mice. Immunofluorescence studies showed influenza A virus NP1 protein and real time polymerase chain reaction (PCR) assay showed RNA in the aorta of infected apo E-deficient mice. Infected mice had significantly higher blood levels of chemokines and cytokines than control mice. At the local level, gene expression for several chemokines and cytokines was increased and eNOS expression was decreased. Infected mice had a higher density of macrophages in plaque than did control mice., Conclusions: We have shown for the first time that influenza virus can directly infect and reside in atherosclerotic arteries and that infection was associated with systemic and arterial-level pro-inflammatory changes., (Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
3. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.
- Author
-
Couch RB, Atmar RL, Cate TR, Quarles JM, Keitel WA, Arden NH, Wells J, Niño D, and Wyde PR
- Subjects
- Administration, Intranasal, Adolescent, Adult, Animals, Antibodies, Viral blood, Cholera Toxin immunology, Humans, Immunity, Mucosal, Influenza A virus immunology, Influenza Vaccines administration & dosage, Influenza, Human prevention & control, Lipid A analogs & derivatives, Lipid A immunology, Mice, Mice, Inbred ICR, Neutralization Tests, Vaccines, Inactivated administration & dosage, Vaccines, Inactivated immunology, Young Adult, Adjuvants, Immunologic administration & dosage, Antibodies, Viral immunology, Influenza Vaccines immunology, Interferon Type I immunology
- Abstract
To identify an adjuvant that enhances antibody responses in respiratory secretions to inactivated influenza virus vaccine (IVV), a comparison was made of responses to intranasal vaccinations of mice with IVV containing monophosphoryl lipid A (MPL), type I interferon (IFN) or cholera toxin B (CTB). Antibody in nasal secretions and lung wash fluids from mice was increased after vaccination and lung virus was significantly reduced after challenge to a similar level in each adjuvant group. Interferon was selected for a trial in humans. Trivalent inactivated influenza vaccine was given intranasally to healthy adult volunteers alone or with 1 million units (Mu) or 10 Mu of alpha interferon. Vaccinations were well tolerated but neither serum hemagglutination-inhibiting nor neutralizing antibody responses among the vaccine groups were significantly different. Similarly, neither neutralizing nor IgA antibody responses in nasal secretions were significantly different. Thus, despite exhibiting a significant adjuvant effect in mice, interferon did not exhibit an adjuvant effect for induction of antibody in respiratory secretions of humans to inactivated influenza virus vaccine given intranasally.
- Published
- 2009
- Full Text
- View/download PDF
4. Evaluation of cotton rats as a model for severe acute respiratory syndrome.
- Author
-
Watts DM, Peters CJ, Newman P, Wang N, Yoshikawa N, Tseng CK, and Wyde PR
- Subjects
- Animals, Chlorocebus aethiops, Female, Male, Pilot Projects, Severe acute respiratory syndrome-related coronavirus physiology, Severe Acute Respiratory Syndrome pathology, Vero Cells, Virus Replication, Disease Models, Animal, Severe Acute Respiratory Syndrome virology, Sigmodontinae
- Abstract
Experimental studies were conducted to evaluate two species of cotton rats, Sigmodon hispidus and Sigmodon fulviventer, as a model for severe acute respiratory syndrome (SARS). Blood and turbinate wash samples, and lung tissue were collected from each animal at different time points after SARS coronavirus (CoV) infection for determining the growth curve of virus, if any, by the standard infectivity assay in Vero E6 cells. In addition, sections of the lung, liver, spleen, and kidney were taken and used for histology analysis. All animals were observed daily for signs of illness, and in some experiments, animals were weighed on the day when they were sacrificed. The results indicated that the cotton rat species, S. hispidus and S. fulviventer, were not a useful model for either SARS-CoV infection or disease. This observation was supported by the absence of any signs of illness, the failure to consistently demonstrate virus in the blood and tissues, and the absent of any notable histopathology. However, infected animals were capable of producing neutralizing antibodies against SARS-CoV, suggesting the seroconversion did occur. Further studies are warranted to consider other animal species in efforts to find better animal models for the evaluation of SARS-CoV vaccines and antiviral drugs.
- Published
- 2008
- Full Text
- View/download PDF
5. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.
- Author
-
Lokugamage KG, Yoshikawa-Iwata N, Ito N, Watts DM, Wyde PR, Wang N, Newman P, Kent Tseng CT, Peters CJ, and Makino S
- Subjects
- Amino Acid Sequence, Animals, Antibodies, Viral blood, Antibodies, Viral immunology, Antibody Specificity, Cell Line, Coronavirus M Proteins, Female, Humans, Injections, Intramuscular, Membrane Glycoproteins genetics, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Neutralization Tests, Reassortant Viruses metabolism, Severe acute respiratory syndrome-related coronavirus metabolism, Sequence Alignment, Severe Acute Respiratory Syndrome blood, Severe Acute Respiratory Syndrome virology, Spike Glycoprotein, Coronavirus, Viral Envelope Proteins genetics, Viral Matrix Proteins metabolism, Viroporin Proteins, Membrane Glycoproteins metabolism, Reassortant Viruses immunology, Severe acute respiratory syndrome-related coronavirus immunology, Severe Acute Respiratory Syndrome prevention & control, Vaccination, Viral Envelope Proteins metabolism, Viral Vaccines administration & dosage
- Abstract
We tested the efficacy of coronavirus-like particles (VLPs) for protecting mice against severe acute respiratory syndrome coronavirus (SCoV) infection. Coexpression of SCoV S protein and E, M and N proteins of mouse hepatitis virus in 293T or CHO cells resulted in the efficient production of chimeric VLPs carrying SCoV S protein. Balb/c mice inoculated with a mixture of chimeric VLPs and alum twice at an interval of four weeks were protected from SCoV challenge, as indicated by the absence of infectious virus in the lungs. The same groups of mice had high levels of SCoV-specific neutralizing antibodies, while mice in the negative control groups, which were not immunized with chimeric VLPs, failed to manifest neutralizing antibodies, suggesting that SCoV-specific neutralizing antibodies are important for the suppression of viral replication within the lungs. Despite some differences in the cellular composition of inflammatory infiltrates, we did not observe any overt lung pathology in the chimeric-VLP-treated mice, when compared to the negative control mice. Our results show that chimeric VLP can be an effective vaccine strategy against SCoV infection.
- Published
- 2008
- Full Text
- View/download PDF
6. Protection against influenza infection by cytokine-enhanced aerosol genetic immunization.
- Author
-
Orson FM, Kinsey BM, Densmore CL, Nguyen T, Wu Y, Mbawuike IN, and Wyde PR
- Subjects
- Animals, Antibody Formation genetics, Cytokines metabolism, Female, Gene Expression, Hemagglutinin Glycoproteins, Influenza Virus genetics, Infusion Pumps, Male, Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections immunology, Plasmids, Immunization methods, Influenza Vaccines, Orthomyxoviridae Infections prevention & control
- Abstract
Background: Conventional vaccine development for newly emerging pandemic influenza virus strains would likely take too long to prevent devastating global morbidity and mortality. If DNA vaccines can be distributed and delivered efficiently, genetic immunization could be an attractive solution to this problem, since plasmid DNA is stable, easily engineered to encode new protein antigens, and able to be quickly produced in large quantities., Methods: We compared two novel genetic immunization methods in a mouse model of influenza to evaluate protective effects: aerosol delivery of polyethylenimine (PEI)-complexed hemagglutinin (HA)-expressing plasmid and intravenous (IV) delivery of the plasmid complexed with macroaggregated albumin/PEI. Serial serum samples were obtained for assay of neutralizing antibodies against HA. Mice were then challenged in the airway with influenza virus, and production of infectious virus in the lungs was titered., Results: Most mice immunized with HA plasmid alone by aerosol and all mice immunized IV developed protective immune responses, whereas none administered control plasmid were protected. Aerosol co-administration of HA plasmid with plasmids encoding the cytokines interleukin 12 (IL12) and granulocyte-macrophage colony stimulating factor (GM-CSF) markedly increased neutralizing antibody responses, so that all aerosol immunized mice were protected from high level virus proliferation., Conclusions: Cytokine-enhanced aerosol delivery of plasmid vaccines can elicit robust protective immune responses against influenza. Thus, aerosol delivery has the potential to address the need for rapid widespread immunization against new influenza virus strains, and may have applications for other infectious and toxic disease processes., (Copyright 2006 John Wiley & Sons, Ltd.)
- Published
- 2006
- Full Text
- View/download PDF
7. Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo.
- Author
-
Yu KL, Wang XA, Civiello RL, Trehan AK, Pearce BC, Yin Z, Combrink KD, Gulgeze HB, Zhang Y, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Wyde PR, Krystal M, and Meanwell NA
- Subjects
- Amines chemistry, Animals, Antiviral Agents adverse effects, Antiviral Agents chemical synthesis, Benzimidazoles adverse effects, Benzimidazoles chemical synthesis, Mice, Molecular Structure, Rats, Sigmodontinae, Solubility, Structure-Activity Relationship, Antiviral Agents chemistry, Antiviral Agents pharmacology, Benzimidazoles chemistry, Benzimidazoles pharmacology, Membrane Fusion drug effects, Respiratory Syncytial Viruses drug effects, Respiratory Syncytial Viruses physiology, Water chemistry
- Abstract
The introduction of acidic and basic functionality into the side chains of respiratory syncytial virus (RSV) fusion inhibitors was examined in an effort to identify compounds suitable for evaluation in vivo in the cotton rat model of RSV infection following administration as a small particle aerosol. The acidic compounds 2r, 2u, 2v, 2w, 2z, and 2aj demonstrated potent antiviral activity in cell culture and exhibited efficacy in the cotton rat comparable to ribavirin. In a BALB/c mouse model, the oxadiazolone 2aj reduced virus titers following subcutaneous dosing, whilst the ester 2az and amide 2aab exhibited efficacy following oral administration. These results established the potential of this class of RSV fusion inhibitors to interfere with infection in vivo following topical or systemic administration.
- Published
- 2006
- Full Text
- View/download PDF
8. A novel inhibitor of respiratory syncytial virus isolated from ethnobotanicals.
- Author
-
Ojwang JO, Wang YH, Wyde PR, Fischer NH, Schuehly W, Appleman JR, Hinds S, and Shimasaki CD
- Subjects
- Antiviral Agents isolation & purification, Cell Culture Techniques, Quinic Acid isolation & purification, Quinic Acid pharmacology, Respiratory Syncytial Virus Infections drug therapy, Antiviral Agents pharmacology, Drugs, Chinese Herbal pharmacology, Plants, Medicinal chemistry, Quinic Acid analogs & derivatives, Respiratory Syncytial Viruses drug effects
- Abstract
A novel low molecular weight compound, CJ 4-16-4, isolated from ethnobotanicals using bioassay-guided fractionation, was found to be a potent inhibitor of respiratory syncytial virus (RSV) in vitro and in vivo. In vitro, a very low micromolar efficacious dose was obtained against at least four of subtype A (RSV-Long, RSV A2, and RSV A6 57754) and one of subtype B (Washington) RSV strains without seeing any significant cytotoxicity to Hep-2, MDCK or Vero cell lines. The drug inhibits growth of RSV in Hep-2 cells maintained in tissue culture at a very low concentration (approximately 0.07 microM) with cell toxicity >400 microM (TI>5880). In a cotton rat model of RSV infection, the drug was able to reduce viral titers by approximately 1 log at dose 12.5 and 25 mg/kg/day, and by >2 log at 100 mg/kg/day. This antiviral activity was specific as influenza A and B and herpes simplex 1 and 2 viruses were not inhibited. The results obtained indicate that CJ 4-16-4 warrants clinical development.
- Published
- 2005
- Full Text
- View/download PDF
9. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol.
- Author
-
Wyde PR, Laquerre S, Chetty SN, Gilbert BE, Nitz TJ, and Pevear DC
- Subjects
- Aerosols, Animals, Antiviral Agents chemistry, Benzhydryl Compounds chemistry, Cell Line, Cytopathogenic Effect, Viral drug effects, Dose-Response Relationship, Drug, Female, Humans, Lung pathology, Male, Phenols chemistry, Respiratory Syncytial Virus Infections pathology, Sigmodontinae, Tetrazoles chemistry, Antiviral Agents administration & dosage, Antiviral Agents pharmacology, Benzhydryl Compounds administration & dosage, Benzhydryl Compounds pharmacology, Phenols administration & dosage, Phenols pharmacology, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Viruses drug effects, Tetrazoles administration & dosage, Tetrazoles pharmacology
- Abstract
VP14637, the lead compound in a series of substituted bis-tetrazole-benzhydrylphenols developed by ViroPharma Incorporated, was evaluated for antiviral efficacy against respiratory syncytial virus (RSV) in vitro in cell culture and in vivo in cotton rats. A selective index of >3000 (> or =2000 times greater than that observed for ribavirin) was determined in the in vitro studies for this compound against both RSV A and B subtypes. In cotton rats, animals given as little as 126 microg drug/kg by small droplet aerosol in divided doses starting 1 day after experimental virus infection with either a RSV A or B subtype consistently had significantly lower mean pulmonary RSV titers and reduced histopathological findings than mock-treated animals or cotton rats given placebo (vehicle-treated animals). No cotton rat treated with aerosols of VP14637 during these studies manifested any evident untoward responses. Thus, VP14637 exhibited good selective antiviral efficacy both in vitro and in vivo.
- Published
- 2005
- Full Text
- View/download PDF
10. Development of a cotton rat-human metapneumovirus (hMPV) model for identifying and evaluating potential hMPV antivirals and vaccines.
- Author
-
Wyde PR, Chetty SN, Jewell AM, Schoonover SL, and Piedra PA
- Subjects
- Animals, Antibodies, Viral blood, Lung pathology, Metapneumovirus immunology, Metapneumovirus pathogenicity, Neutralization Tests, Rats, Antibodies, Viral immunology, Antiviral Agents pharmacology, Disease Models, Animal, Lung virology, Metapneumovirus drug effects, Viral Vaccines immunology
- Abstract
Hispid cotton rats were inoculated with two different human metapneumovirus (hMPV) subtype A strains and one subtype B hMPV. Although no overt disease was seen in any virus-inoculated animal, following an eclipse phase, significant pulmonary virus titers were observed in every hMPV-inoculated animal through day 7 post virus inoculation (p.i.) and in most through day 10. Peak virus titers occurred four days p.i., while virus-induced histopathology was most evident in lung sections obtained from animals 7 to 10 days p.i. The latter consisted primarily of desquamating and hypertrophic columnar epithelial cells lining the bronchi and bronchioles and the presence of large numbers of leukocytes in and around the bronchi and bronchioles. In fluorescent antibody studies, virus antigen-specific fluorescence was most evident in the desquamating tall columnar epithelial cells lining bronchi and bronchioles, in pneumocytes lining alveoli and in single or small groups of free cells, most probably leukocytes, present in the lumen of alveoli, bronchi and bronchioles. Virus was generally not detected in inoculated animals >10 days p.i. Although the pattern of virus replication in cotton rats was similar for all the three virus stains, the B subtype consistently grew to lower levels than the two A strains. Regardless, these findings indicate that hMPV replicates in cotton rats and that these animals may be used as a small animal model of hMPV infection and to facilitate the identification and development of vaccines and antivirals for preventing and/or ameliorating infections caused by this virus.
- Published
- 2005
- Full Text
- View/download PDF
11. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays.
- Author
-
Wyde PR, Moylett EH, Chetty SN, Jewell A, Bowlin TL, and Piedra PA
- Subjects
- Animals, Antiviral Agents administration & dosage, Chlorocebus aethiops, Culture Techniques, Heparin, Humans, Metapneumovirus growth & development, Metapneumovirus immunology, Metapneumovirus physiology, Microbial Sensitivity Tests, Respiratory Syncytial Virus, Human growth & development, Respiratory Syncytial Virus, Human immunology, Respiratory Syncytial Virus, Human physiology, Vero Cells, Virus Replication drug effects, Antiviral Agents pharmacology, Lipids pharmacology, Metapneumovirus drug effects, N-Acetylneuraminic Acid analogs & derivatives, N-Acetylneuraminic Acid pharmacology, Respiratory Syncytial Virus, Human drug effects
- Abstract
Human metapneumovirus (hMPV) is a recently elucidated respiratory virus pathogen for which there are no agents currently licensed to prevent or treat infections caused by it. However, NMSO3 has been reported to inhibit replication of human respiratory syncytial virus (hRSV), a virus that is closely related to hMPV, both in vitro in tissue culture cells and in vivo in cotton rats. For this reason, experiments were performed to compare the antiviral activity of NMSO3 against both hRSV and hMPV in tissue culture-based assays. Heparin and ribavirin, two other compounds known to inhibit hRSV, and two other paramyxoviruses, human parainfluenza virus type 3 (PIV3) and measles virus (MV), were included in these tests for comparison. All three compounds significantly inhibited the replication of subtype A and B strains of hRSV and serotypes 1 and 2 hMPV. However, unlike ribavirin, NMSO3 and heparin inhibited only hMPV and hRSV and not PIV3 or MV. Also unlike ribavirin, the activity of the two sulfated molecules was most effective if these materials were present during virus attachment and penetration of host cells. Interestingly, NMSO3, but not heparin, was able to limit secondary infection and spread of both viruses.
- Published
- 2004
- Full Text
- View/download PDF
12. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection.
- Author
-
Wyde PR, Chetty SN, Timmerman P, Gilbert BE, and Andries K
- Subjects
- Administration, Inhalation, Aerosols, Animals, Antiviral Agents pharmacokinetics, Antiviral Agents therapeutic use, Antiviral Agents toxicity, Benzimidazoles therapeutic use, Drug Evaluation, Preclinical, Female, Lung metabolism, Lung virology, Male, Piperidines therapeutic use, Pyridines therapeutic use, Respiratory Syncytial Viruses growth & development, Sigmodontinae, Antiviral Agents administration & dosage, Benzimidazoles administration & dosage, Piperidines administration & dosage, Pyridines administration & dosage, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Viruses drug effects
- Abstract
Cotton rats exposed to continuous small droplet aerosols of 2[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol (JNJ 2408068) or its hydrochloric salt for only 15 min, one day prior to virus inoculation or one day after, were significantly protected from pulmonary respiratory syncytial virus (RSV) infection compared to control animals similarly infected but exposed to aerosols of placebo at these times. No evidence of toxicity was seen in any of these animals or in cotton rats administered 10 times the minimum cotton rat efficacious dose (i.e. 10x0.39 mg of active compound per kilogram of body weight) for four continuous days. The marked selective antiviral activity observed in the cotton rats mirrored that seen for these compounds in cytotoxicity and antiviral assays performed against RSV in vitro. Plasma kinetics and tissue distribution of JNJ 2408068 in cotton rats following inhalation were determined in separate experiments performed using conditions similar to those utilized in the in vivo efficacy studies. The data from these experiments indicated that significant levels of the test compound were delivered to the lungs of exposed animals, but that extrapulmonary distribution was limited.
- Published
- 2003
- Full Text
- View/download PDF
13. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus.
- Author
-
Andries K, Moeremans M, Gevers T, Willebrords R, Sommen C, Lacrampe J, Janssens F, and Wyde PR
- Subjects
- Antiviral Agents chemistry, Cell Fusion, Cytokines metabolism, Cytopathogenic Effect, Viral drug effects, DNA Mutational Analysis, Drug Resistance, Viral genetics, HeLa Cells, Humans, Metapneumovirus drug effects, Metapneumovirus growth & development, Molecular Weight, Morbillivirus drug effects, Morbillivirus growth & development, Point Mutation, Respiratory Syncytial Viruses growth & development, Respiratory Syncytial Viruses isolation & purification, Respiratory Syncytial Viruses pathogenicity, Respirovirus drug effects, Respirovirus growth & development, Rubulavirus drug effects, Rubulavirus growth & development, Viral Fusion Proteins genetics, Viral Plaque Assay, Antiviral Agents pharmacology, Benzimidazoles chemistry, Benzimidazoles pharmacology, Respiratory Syncytial Viruses drug effects
- Abstract
A cell-based assay was used to discover compounds inhibiting respiratory syncytial virus (RSV)-induced fusion in HeLa/M cells. A lead compound was identified and subsequent synthesis of >300 analogues led to the identification of JNJ 2408068 (R170591), a low molecular weight (MW 395) benzimidazole derivative with an EC(50) (0.16 nM) against some lab strains almost 100,000 times better than that of ribavirin (15 microM). Antiviral activity was confirmed for subgroup A and B clinical isolates of human RSV and for a bovine RSV isolate. The compound did not inhibit the growth of representative viruses from other Paramyxovirus genera, i.e. HPIV2 and Mumps Virus (genus Rubulavirus), HPIV3 (genus Respirovirus), Measles virus (genus Morbillivirus) and hMPV. Efficacy in cytopathic effect inhibition assays correlated well with efficacy in virus yield reduction assays. A concentration of 10nM reduced RSV production 1000-fold in multi-cycle experiments, irrespective of the multiplicity of infection. Time of addition studies pointed to a dual mode of action: inhibition of virus-cell fusion early in the infection cycle and inhibition of cell-cell fusion at the end of the replication cycle. Two resistant mutants were raised and shown to have single point mutations in the F-gene (S398L and D486N). JNJ 2408068 was also shown to inhibit the release of proinflammatory cytokines IL-6, IL-8 and Rantes from RSV-infected A549 cells.
- Published
- 2003
- Full Text
- View/download PDF
14. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro.
- Author
-
Wyde PR, Chetty SN, Jewell AM, Boivin G, and Piedra PA
- Subjects
- Animals, Antibodies, Monoclonal immunology, Antibodies, Viral immunology, Antiviral Agents pharmacology, Cell Line, Cell Line, Tumor, Female, Humans, Male, Metapneumovirus growth & development, Mice, Mice, Inbred BALB C, Neutralization Tests, Rats, Respiratory Syncytial Virus, Human growth & development, Sigmodontinae, Virus Replication drug effects, Immunoglobulins, Intravenous immunology, Metapneumovirus drug effects, Metapneumovirus immunology, Respiratory Syncytial Virus, Human drug effects, Respiratory Syncytial Virus, Human immunology, Ribavirin pharmacology
- Abstract
Human metapneumovirus (hMPV) is a newly recognized pathogen that like its better-known relative, human respiratory syncytial virus (hRSV), appears to be ubiquitous and an important cause of respiratory disease in diverse subpopulations. No antivirals or vaccines are currently approved for the treatment or prevention of hMPV infections. However, ribavirin is licensed to treat serious hRSV-induced infections in children and immune globulin designed for intravenous administration (i.v.IG) and palivizumab (Synagis), a humanized monoclonal antibody preparation, have been utilized as alternatives to vaccines for preventing or reducing the severity of infections caused by this virus. Because both ribavirin and i.v.IG have broad viral specificities, studies were performed to compare the ability of these two agents to inhibit the replication of hRSV and hMPV in tissue culture-based assays. Two experimental chemotherapeutic agents (i.e. VP14637 and JNJ2408068) and different antibody preparations were included in this testing for comparison. Ribavirin and the i.v.IG utilized were found to have equivalent antiviral activity against hMPV and hRSV. In contrast, except for antisera specifically raised against hMPV, all of the other materials tested had marked activity only against hRSV.
- Published
- 2003
- Full Text
- View/download PDF
15. Modulation of gamma delta T cells in mouse buccal epithelium following antigen priming.
- Author
-
Otten K, Wang HC, Wyde PR, and Klein JR
- Subjects
- Animals, Female, Gene Expression Regulation immunology, Genes, Immunoglobulin, Mice, Mice, Inbred BALB C, Polymerase Chain Reaction, Receptors, Antigen, T-Cell, gamma-delta genetics, Antigen Presentation, Immunity, Mucosal, Mouth Mucosa immunology, Receptors, Antigen, T-Cell, gamma-delta immunology, T-Lymphocytes immunology
- Abstract
T cells using the gamma delta T cell receptor (TCR) are abundant in mucosal and epidermal tissues in mice. Most studies of mucosal gamma delta T cells, however, have examined cells from the intestinal mucosa, whereas little is known about the presence or function of gamma delta T cells in the oral cavity. To better understand the involvement of oral gamma delta T cells in immunity, we have characterized TCR variable gamma-gene usage in the buccal epithelium from normal mice, and from mice challenged locally with a non-replicating antigen (bovine serum albumin [BSA]) or by influenza-virus infection as a replicating antigen. Our findings demonstrate a restricted use of V gamma genes by buccal gamma delta T cells, consisting primarily of V gamma 1.2, V gamma 3, and V gamma 5, with minimal use of V gamma 2 and V gamma 4 genes. Of particular interest, 3-4 days post-antigen challenge with BSA, there was a precipitous drop in the level of expression of V gamma 1.2, V gamma 3, and V gamma 5 genes, and to a lesser extent for the V gamma 2 gene, whereas V gamma 4 gene expression increased between days 1 and 2 post-priming. In influenza-infected mice, a similar pattern was observed for the V gamma 2 and V gamma 5 genes, but not other V gamma genes. The immune-modulating effects of oral antigen exposure on buccal gamma delta T cells suggest that these cells are functionally involved in the local immune response to both replicating and non-replicating antigens in oral mucosal surfaces.
- Published
- 2002
- Full Text
- View/download PDF
16. In vitro Inhibition of HHV-6 replication by sophocarpines.
- Author
-
Qavi HB, Wyde PR, and Khan MA
- Subjects
- Cell Survival drug effects, Dose-Response Relationship, Drug, Herpesvirus 6, Human pathogenicity, Humans, Inhibitory Concentration 50, Plant Extracts pharmacology, Tumor Cells, Cultured drug effects, Virus Replication drug effects, Alkaloids pharmacology, Antiviral Agents pharmacology, Ganciclovir pharmacology, Herpesvirus 6, Human drug effects, Sophora
- Abstract
The virostatic activity of sophocarpines and gancyclovir (GCV) was tested using HHV-6 Z29 strain and Molt-3 cells. The cytotoxic (IC(50)) and the antiviral (ED(50)) values were first experimentally determined and selective indices (SI) were then calculated. The SI values for sophocarpines 1 and 2 and GCV were in the order 184, 183, and 23, respectively. Though preliminary, these findings indicate that sophocarpines have the potential to inhibit HHV-6 replication., (Copyright 2002 John Wiley & Sons, Ltd.)
- Published
- 2002
- Full Text
- View/download PDF
17. An aged mouse model for RSV infection and diminished CD8(+) CTL responses.
- Author
-
Zhang Y, Wang Y, Gilmore X, Xu K, Wyde PR, and Mbawuike IN
- Subjects
- Animals, Cytotoxicity, Immunologic physiology, Disease Models, Animal, Interferon-gamma immunology, Interleukin-4 immunology, Mice, Mice, Inbred BALB C, Respiratory Syncytial Virus Infections physiopathology, Aging immunology, CD8-Positive T-Lymphocytes immunology, Respiratory Syncytial Virus Infections immunology, Respiratory Syncytial Viruses immunology
- Abstract
Recent studies indicate that respiratory syncytial virus (RSV), like influenza, causes significant morbidity and mortality among elderly persons. There are currently no animal models to study the effects of aging on RSV disease and immunity. This manuscript provides an initial description of such a model. Aged and young BALB/c mice (22-24 and 2-4 months, respectively) were infected with 10(4) TCID(50) of RSV A2. RSV was detected by culture in lung and nose wash specimens obtained 4-6 days following infection at a slightly higher titer in old mice in comparison with young mice. RT-PCR assay detected RSV in the lungs and nose washes of all mice on 4, 8, and 21 days postinoculation, with only a slightly less frequency in young mice. Splenic lymphocytes from old mice exhibited significantly lower RSV-specific MHC class I-restricted CD8(+) CTL responses (P < 0.01-0001), and reduced IFN-production (P < 0.03) than young mice. Conversely, IL-4 production was somewhat elevated in old mice. These results demonstrate diminished RSV virus-specific CD8(+)CTL responses and IFN-gamma production in old mice in comparison with young. It is speculated that the deficient RSV-specific CTL responses may account for the increased morbidity and mortality from RSV infections in elderly persons. Although detailed histopathological, virological, and immunological analyses are incomplete at present, the old BALB/c RSV infection model described provides an opportunity to evaluate the role of CD8(+)CTL and cytokines in RSV disease in aging.
- Published
- 2002
- Full Text
- View/download PDF
18. Use of cotton rats for preclinical evaluation of measles vaccines.
- Author
-
Wyde PR, Stittelaar KJ, Osterhaus AD, Guzman E, and Gilbert BE
- Subjects
- Animals, Antibodies, Viral analysis, Disease Models, Animal, Drug Evaluation, Preclinical methods, Female, Immunization, Passive, Lung pathology, Male, Measles pathology, Rats, Sigmodontinae, Vaccines, Synthetic administration & dosage, ISCOMs administration & dosage, Measles prevention & control, Measles Vaccine administration & dosage, Measles virus immunology
- Abstract
The continued prevalence and medical impact of measles worldwide has created interest in the development of new generations of measles vaccines. Monkeys can be used for preclinical testing of these vaccines. However, a more practical and less expensive animal model is highly desirable, particularly for initial vaccine development and evaluation. Cotton rats have been shown to support the replication of different strains of measles virus (MV), and thus may be useful for these purposes. To test this concept, the immunogenicity and protective efficacy of two standard (Moraten and trivalent measles, mumps, rubella) and four experimental (two recombinant ALVAC, one ISCOM subunit and live attenuated Edmonston-Zagreb) MV vaccines were evaluated in naïve cotton rats, and cotton rats with passively acquired MV-specific neutralizing serum antibodies. All of the test vaccines were immunogenic and protected naíve animals from pulmonary infection and viral dissemination. However, under the conditions utilized, only the Edmonston-Zagreb vaccine provided such protection to animals with significant levels of passively acquired MV-specific neutralizing antibodies. The results of these tests and the potential of using cotton rats as an animal model for preliminary testing of MV vaccines are discussed.
- Published
- 2000
- Full Text
- View/download PDF
19. Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections.
- Author
-
Wyde PR, Moore-Poveda DK, De Clercq E, Neyts J, Matsuda A, Minakawa N, Guzman E, and Gilbert BE
- Subjects
- Animals, Antiviral Agents pharmacology, Disease Models, Animal, Measles virus drug effects, Mice, Microbial Sensitivity Tests, Polymers pharmacology, Rats, Ribavirin pharmacology, Ribonucleosides pharmacology, Sigmodontinae, Sulfonic Acids pharmacology, Tumor Cells, Cultured, Antiviral Agents therapeutic use, Measles drug therapy, Polymers therapeutic use, Ribavirin therapeutic use, Ribonucleosides therapeutic use, Sulfonic Acids therapeutic use
- Abstract
No practical animal models for the testing of chemotherapeutic or biologic agents identified in cell culture assays as being active against measles virus (MV) are currently available. Cotton rats may serve this purpose. To evaluate this possibility, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) and poly(acrylamidomethyl propanesulfonate) (PAMPS), two compounds that have been reported to inhibit MV in vitro, and ribavirin, an established antiviral drug with MV-inhibitory activity, were evaluated for their antiviral activities against MV and respiratory syncytial virus (RSV) in tissue culture and in hispid cotton rats. A single administration of PAMPS markedly inhibited pulmonary RSV or MV replication (>3 log(10) reduction in pulmonary titer compared to that for controls), but only if this compound was administered intranasally at about the time of virus inoculation. Both EICAR and ribavirin exhibited therapeutic activity against RSV and MV in cotton rats when they were administered parenterally. However, both of these compounds were less effective against MV. On the basis of the pulmonary virus titers on day 4 after virus inoculation, the minimal efficacious dose of EICAR against MV (120 mg/kg of body weight/day when delivered intraperitoneally twice daily) appeared to be three times lower against this virus than that of ribavirin delivered at a similar dose (i.e., 360 mg/kg/day). These findings correlated with those obtained in vitro. The data obtained suggest that cotton rats may indeed be useful for the initial evaluation of the activities of antiviral agents against MV.
- Published
- 2000
- Full Text
- View/download PDF
20. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.
- Author
-
Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, Hamilton WJ, Rojas-Martinez A, Chen SH, Woo SL, and Grossman RG
- Subjects
- Adenoviridae immunology, Adult, Aged, Antiviral Agents administration & dosage, Astrocytoma genetics, Astrocytoma mortality, Astrocytoma therapy, Avian Sarcoma Viruses genetics, Brain Neoplasms diagnostic imaging, Brain Neoplasms mortality, Combined Modality Therapy, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Ganciclovir administration & dosage, Genetic Vectors administration & dosage, Glioblastoma diagnostic imaging, Glioblastoma genetics, Glioblastoma mortality, Glioblastoma therapy, Gliosarcoma genetics, Gliosarcoma mortality, Gliosarcoma therapy, Humans, Male, Middle Aged, Promoter Regions, Genetic, Radiography, Time Factors, Treatment Outcome, Adenoviridae genetics, Antiviral Agents pharmacology, Brain Neoplasms genetics, Brain Neoplasms therapy, Ganciclovir pharmacology, Genetic Therapy, Simplexvirus enzymology, Thymidine Kinase genetics
- Abstract
Between December 1996 and September 1998, 13 patients with advanced recurrent malignant brain tumors (9 with glioblastoma multiforme, 1 with gliosarcoma, and 3 with anaplastic astrocytoma) were treated with a single intratumoral injection of 2 x 10(9), 2 x 10(10), 2 x 10(11), or 2 x 10(12) vector particles (VP) of a replication-defective adenoviral vector bearing the herpes simplex virus thymidine kinase gene driven by the Rous sarcoma virus promoter (Adv.RSVtk), followed by ganciclovir (GCV) treatment. The VP to infectious unit ratio was 20:1. Our primary objective was to determine the safety of this treatment. Injection of Adv.RSVtk in doses <==2 x 10(11) VP, followed by GCV, was safely tolerated. Patients treated with the highest dose, 2 x 10(12) VP, exhibited central nervous system toxicity with confusion, hyponatremia, and seizures. One patient is living and stable 29.2 months after treatment. Two patients survived >25 months before succumbing to tumor progression. Ten patients died within 10 months of treatment, 9 from tumor progression and 1 with sepsis and endocarditis. Neuropathologic examination of postmortem tissue demonstrated cavitation at the injection site, intratumoral foci of coagulative necrosis, and variable infiltration of the residual tumor with macrophages and lymphocytes.
- Published
- 2000
- Full Text
- View/download PDF
21. Chemotherapy of respiratory viruses: prospects and challenges.
- Author
-
Wyde PR
- Abstract
Billions of people are infected with respiratory viruses annually. Infants and young children, the elderly, immunocompromised individuals and those debilitated by other diseases or nutritional deficiencies are most at risk for serious disease. There are few vaccines available for use against these viruses, and even where there are (influenza, measles and adenovirus), infections remain common. The continued prevalence of respiratory virus infections has lead to renewed efforts to find safe agents effective against the most medically important respiratory viruses: influenza, respiratory syncytial, parainfluenza, measles, rhino- and adenovirus. Copyright 1999 Harcourt Publishers Ltd.
- Published
- 1999
- Full Text
- View/download PDF
22. Replication of clinical measles virus strains in hispid cotton rats.
- Author
-
Wyde PR, Moore-Poveda DK, Daley NJ, and Oshitani H
- Subjects
- Administration, Intranasal, Animals, Cells, Cultured, Disease Models, Animal, Female, Humans, Kinetics, Leukocytes virology, Lung pathology, Lung virology, Male, Measles immunology, Measles Vaccine pharmacology, Measles virus pathogenicity, Mice, Mice, Inbred BALB C, Species Specificity, Virus Replication, Measles etiology, Measles virology, Measles virus physiology, Sigmodontinae virology
- Abstract
An alternative model to nonhuman primates to study measles virus (MV) pathogenesis, to evaluate potential MV vaccines, or to screen for potential antivirals effective against this virus is highly desirable. The laboratory-adapted Edmonston strain of MV has been reported to replicate in the lungs of hispid cotton rats following intranasal inoculation, immunosuppress infected animals, and disseminate widely from the lungs, making these animals a candidate model. However, clinical MV strains have generally not been found to grow in these animals, limiting the utility and acceptance of this model. In the present studies we demonstrate reproducible replication of several clinical MV strains in hispid cotton rats. As with the Edmonston strain, leukocytes appear to be the primary target cells of these viruses following intranasal inoculation, and extrapulmonary dissemination is common. It is also demonstrated that prior MV infection or immunization of test animals with MV vaccine prevents pulmonary tract infection. These findings should make the MV-cotton rat model more acceptable.
- Published
- 1999
- Full Text
- View/download PDF
23. Distribution, persistency, toxicity, and lack of replication of an E1A-deficient adenoviral vector after intracardiac delivery in the cotton rat.
- Author
-
Rojas-Martinez A, Wyde PR, Montgomery CA, Chen SH, Woo SL, and Aguilar-Cordova E
- Subjects
- Animals, Cricetinae, DNA, Viral analysis, Defective Viruses genetics, Dose-Response Relationship, Drug, Ganciclovir administration & dosage, Genetic Vectors adverse effects, Heart, Humans, Myocardium pathology, Simplexvirus enzymology, Simplexvirus genetics, Time Factors, Tissue Distribution, Virus Replication, Adenovirus E1A Proteins genetics, Gene Transfer Techniques, Genetic Vectors administration & dosage, Mastadenovirus genetics, Sigmodontinae, Thymidine Kinase genetics
- Abstract
Adenoviral vectors were inoculated via intracardiac injection into 5- to 1O-week-old cotton rats (Sigmodon hispidus) to evaluate the effects of systemic delivery. Cotton rats were chosen as a model because they are semipermissive to the replication of human adenoviruses. The vector used was AdV.RSV-tk, a replication-deficient adenovirus with a herpes simplex virus thymidine kinase gene inserted in the E1 region. Vector doses were 3 x 10(8), 3 x 10(9), and 3 x 10(10) viral particles per animal with and without ganciclovir at 10 mg/kg twice a day. Animals were sacrificed and necropsied at 24 hours, 7 days, and 14 days postinoculation. Gross and microscopic pathologic observations in dosed groups were compared with an unmanipulated control group. From each animal, 10 different organ systems were analyzed for histopathology and vector distribution. The only significant microscopic lesions observed were epicardial inflammation and splenic hemosiderosis. Vector sequences persisted throughout the 14-day assay with preponderance in the heart, lung, and lymphoid organs. Infectious virions were detected for 24 hours, and these virions were only detected at the site of injection of two animals in the highest dose group. No viral replication was detected. Therefore, systemic delivery of up to 3 x 10(11) viral particles/kg was well tolerated in this semipermissive host model and did not result in any significant pathology.
- Published
- 1998
24. Respiratory syncytial virus (RSV) disease and prospects for its control.
- Author
-
Wyde PR
- Subjects
- Adjuvants, Immunologic therapeutic use, Adult, Antiviral Agents therapeutic use, Child, Humans, Immunization, Passive, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections epidemiology, Viral Vaccines therapeutic use, Respiratory Syncytial Virus Infections prevention & control
- Abstract
Respiratory syncytial virus (RSV) is a major virus pathogen of infants and young children, an important cause of disease in adults and is responsible for a significant amount of excess morbidity and mortality in the elderly. It also can be devastating in immunosuppressed populations. Vaccines are being developed, but none are currently licensed. Moreover, even if one or more are approved, they may not be suitable for some populations vulnerable to RSV (e.g. very young infants and the immunosuppressed). Ribavirin and immunoglobulin preparations with high titers of RSV-specific neutralizing antibodies are currently approved for use to treat and prevent RSV infection. However, neither of these is cost-effective or simple to administer. New agents are needed to reduce the impact of RSV. This review is concerned with the means currently available for controlling RSV, the search for new agents effective against this virus, and future prospects for preventing and treating RSV infections.
- Published
- 1998
- Full Text
- View/download PDF
25. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults.
- Author
-
Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, Yousuf H, Regnery H, Klimov AI, Cox NJ, and Whimbey E
- Subjects
- Adult, Bone Marrow Transplantation adverse effects, Drug Resistance, Microbial, Humans, Influenza, Human etiology, Leukemia complications, Middle Aged, Opportunistic Infections drug therapy, Opportunistic Infections etiology, Amantadine therapeutic use, Antiviral Agents therapeutic use, Influenza A virus drug effects, Influenza, Human drug therapy, Opportunistic Infections virology, Rimantadine therapeutic use
- Abstract
The importance and significance of amantadine- or rimantadine-resistant influenza viruses in immunocompromised patients was studied in a population of adult bone marrow transplant (BMT) recipients and patients with leukemia prospectively cultured for respiratory viruses. Influenza A viruses were isolated from 29 patients with acute respiratory illness (14 BMT recipients and 15 patients with leukemia). Fifteen patients (52%) received amantadine (n = 4) or rimantadine (n = 11) therapy. All influenza isolates recovered from six patients shedding virus for > or = 3 days were screened for antiviral susceptibility; resistant isolates were further genetically characterized. Initial influenza isolates were susceptible to amantadine or rimantadine, but subsequent isolates from five of six patients were resistant. Influenza-associated mortality was similar among patients with and without documented antiviral resistance (2 of 5 vs. 5 of 24). We conclude that development of antiviral resistance in immunocompromised individuals should be considered when they have been treated with antivirals and have shed influenza virus for a prolonged period. Isolation procedures should be instituted for all immunocompromised patients with influenza, both during and after therapy with amantadine or rimantadine.
- Published
- 1998
- Full Text
- View/download PDF
26. CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats.
- Author
-
Wyde PR, Moore-Poveda DK, O'Hara B, Ding WD, Mitsner B, and Gilbert BE
- Subjects
- Animals, Antiviral Agents administration & dosage, Antiviral Agents chemistry, Antiviral Agents toxicity, Chlorocebus aethiops, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Administration Routes, Drug Administration Schedule, Female, Humans, Male, Molecular Structure, Rats, Sigmodontinae, Triazines chemistry, Triazines toxicity, Tumor Cells, Cultured, Vero Cells, Antiviral Agents pharmacology, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus, Human drug effects, Triazines pharmacology
- Abstract
CL387626 (4,4'-Bis[4,6-di[3-aminophenyl-N,N-bis(2-carbamoylethyl)-sulfon ilimino]-1,3,5-triazine-2-ylamino-bi-phenyl-2,2'-disulfonic acid, disodium salt), a compound synthesized by Wyeth-Ayerst Research Laboratories, was tested for its cytotoxicity and antiviral activity against respiratory syncytial virus (RSV) in tissue culture and in cotton rats. The median cell inhibitory (IC50) and median efficacious (EC50) concentrations of CL387626 against RSV in proliferating HEp2 or Vero tissue culture cells were determined to be 375 and 0.25 microg/ml, respectively, giving the compound an apparent selective index (S.I.) of 1500. This compound also exhibited uncommon antiviral activity against RSV in cotton rats. In multiple experiments, a single 30 mg/kg dose of CL387626 administered intranasally 4 or 5 days prior to virus challenge, significantly inhibited pulmonary replication of RSV compared to that seen in control animals inoculated similarly with placebo (i.e. water). In contrast to these results, most lots of CL387626 failed to significantly inhibit pulmonary RSV replication when administered utilizing therapeutic administration schedules. Although some cytotoxicity was noted in tissue culture assays, no overt toxic effects were noted in any test animal, including those inoculated with > 300 mg CL387626/kg, a dose approximately 150 times the apparent minimal efficacious dose (i.e. 1.9 mg/kg).
- Published
- 1998
- Full Text
- View/download PDF
27. Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs.
- Author
-
Lukomski S, Burns EH Jr, Wyde PR, Podbielski A, Rurangirwa J, Moore-Poveda DK, and Musser JM
- Subjects
- Animals, Bacterial Proteins, Male, Mice, Neutrophils physiology, Streptococcus pyogenes immunology, Streptococcus pyogenes pathogenicity, Virulence, Cysteine Endopeptidases physiology, Phagocytosis, Streptococcus pyogenes enzymology
- Abstract
Streptococcal pyrogenic exotoxin B (SpeB), a conserved cysteine protease expressed by virtually all Streptococcus pyogenes strains, has recently been shown to be an important virulence factor (S. Lukomski, S. Sreevatsan, C. Amberg, W. Reichardt, M. Woischnik, A. Podbielski, and J. M. Musser, J. Clin. Invest. 99:2574-2580, 1997). Genetic inactivation of SpeB significantly decreased the lethality of a serotype M49 strain for mice and abolished the lethality of a serotype M3 strain after intraperitoneal (i.p.) injection. In the present study, a wild-type M3 isolate and an M3 speB mutant derivative were used to investigate the mechanism responsible for altered virulence. Following i.p. injection, the mutant and wild-type strains induced virtually identical cellular inflammatory responses, characterized largely by an influx of polymorphonuclear leukocytes (PMNs). In addition, the mutant and wild-type strains rapidly entered the blood and were recovered from all organs examined. However, significantly fewer (P < 0.05) CFUs of the isogenic mutant derivative than of the wild-type parent strain were recovered from blood and organs. PMNs effectively cleared the M3 speB mutant from the peritoneum by 22 h, thereby sparing the host. In contrast, the wild-type M3 strain continued to replicate intraperitoneally and had the ability to kill phagocytes. This process allowed the wild-type strain to continuously disseminate, resulting in host death. Our results indicate that genetic inactivation of the cysteine protease decreased the resistance of the mutant to phagocytosis and impaired its subsequent dissemination to organs. These results provide insight into the detrimental effect of SpeB inactivation on virulence.
- Published
- 1998
- Full Text
- View/download PDF
28. The cotton rat in biomedical research.
- Author
-
Faith RE, Montgomery CA, Durfee WJ, Aguilar-Cordova E, and Wyde PR
- Subjects
- Adenoviridae, Animal Husbandry methods, Animals, Female, Genetic Therapy methods, Genetic Vectors, Male, Rats, Rodent Diseases pathology, Sigmodontinae virology, Research, Sigmodontinae physiology
- Published
- 1997
29. Recombinant superoxide dismutase (SOD) administered by aerosol inhibits respiratory syncytial virus infection in cotton rats.
- Author
-
Wyde PR, Moore DK, Pimentel DM, Gilbert BE, Nimrod R, and Panet A
- Subjects
- Aerosols, Animals, Antiviral Agents metabolism, Antiviral Agents toxicity, Chlorocebus aethiops, Copper, Dose-Response Relationship, Drug, Humans, Lung metabolism, Manganese, Recombinant Fusion Proteins genetics, Respiratory Syncytial Virus Infections metabolism, Respiratory Syncytial Virus Infections virology, Sigmodontinae, Superoxide Dismutase genetics, Superoxide Dismutase metabolism, Superoxide Dismutase toxicity, Tumor Cells, Cultured, Vero Cells, Zinc, Antiviral Agents pharmacology, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Viruses drug effects, Superoxide Dismutase pharmacology
- Abstract
Recombinant (r) human (hu) manganese (Mn) and copper-zinc (CuZn) superoxide dismutase (SOD) were evaluated for their cytotoxicity and antiviral activity against respiratory syncytial virus (RSV) in tissue culture and in cotton rats. No apparent cytotoxicity or inhibition of RSV was observed in the tissue culture studies (both compounds had IC50 and EC50 values > or = 1000 micrograms/ml and a selective index = 1). However, significant reductions in mean pulmonary RSV titers (ranging between 0.5 and 1.9 log10/g of lung compared with the mean pulmonary viral titers detected in similarly inoculated, placebo-treated control animals) were seen in most of the experiments, in which experimentally infected cotton rats were exposed to continuous small-particle aerosols (reservoir concentrations > or = 20 mg/ml) containing either rhuMnSOD or rhuCuZnSOD. This protective effect was dose dependent and not observed when either rSOD compound was administered parenterally (intraperitoneally) or intranasally. No toxic effects were noted in any of the cotton rats exposed to aerosols of either rhuMn or CuZnSOD; nor was any evidence of drug-induced histopathology observed in sections of lung prepared from these animals.
- Published
- 1996
- Full Text
- View/download PDF
30. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
- Author
-
Wyde PR, Moore DK, Hepburn T, Silverman CL, Porter TG, Gross M, Taylor G, Demuth SG, and Dillon SB
- Subjects
- Animals, Antibodies, Monoclonal pharmacokinetics, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antibodies, Viral blood, Bronchoalveolar Lavage Fluid immunology, Disease Models, Animal, Evaluation Studies as Topic, Humans, Immunization, Passive, In Vitro Techniques, Infant, Lung pathology, Neutralization Tests, Respiratory Syncytial Virus Infections immunology, Respiratory Syncytial Virus Infections therapy, Sigmodontinae, Viral Fusion Proteins immunology, Antibodies, Monoclonal pharmacology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Viruses immunology
- Abstract
Reshaped human MAb RSHZ19, which is specific for the surface fusion protein of respiratory syncytial virus (RSV) is in clinical development for the prevention and treatment of RSV-induced disease in human infants. The current studies profile lung virus clearance and evaluate lung histopathology in MAb-treated, RSV-infected cotton rats, a well characterized model of RSV infection. The highest dose of this MAb (10 mg/kg) administered parenterally 24 h before infection decreased subgroup A or B RSV lung titers to below detectable levels (> or = 2.3 log10 reduction), and significantly reduced lung virus titers (> or = 2.0 log10 reduction) when administered 96 h postinfection. Prophylactic administration of 10 mg/kg RSHZ19 was significantly more protective than 1000 mg/kg conventional human immune serum globulin (HSIg), and protective serum-neutralizing titers in MAb-treated animals (1:32, which correlated with approximately 40 micrograms/ml determined by anti-idiotype ELISA) were significantly lower than those reported previously for HSIg or for convalescent human serum (1:200-1:400). MAb concentration in lung lavages was determined by ELISA to be approximately 1% of the serum MAb concentration, but was not detectable by neutralization assay. The degree of lung histopathology in MAb-treated cotton rats was proportional to lung virus titer, and inversely proportional to the RSHZ19 dose administered. There was no evidence of exacerbated disease in the lungs of MAb-treated animals. These studies thus support the potential clinical utility of RSHZ19 MAb in the prevention and treatment of RSV-induced disease in humans.
- Published
- 1995
- Full Text
- View/download PDF
31. Protection of mice against lethal viral infection by synthetic peptides corresponding to B- and T-cell recognition sites of influenza A hemagglutinin.
- Author
-
Simeckova-Rosenberg J, Yun Z, Wyde PR, and Atassi MZ
- Subjects
- Amino Acid Sequence, Animals, Female, Hemagglutinin Glycoproteins, Influenza Virus, Hemagglutinins, Viral chemistry, Influenza A virus chemistry, Influenza Vaccines chemistry, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections prevention & control, Peptides chemical synthesis, Peptides therapeutic use, Hemagglutinins, Viral immunology, Influenza A virus immunology, Influenza Vaccines immunology, Peptides immunology
- Abstract
Previously, we reported 12 synthetic T- and B-cell recognition regions representing surface areas of the hemagglutinin (HA) of X31 influenza virus. In the present study, four of these peptides were examined in Balb/c mice for their ability to produce protective immunity against lethal infection with a dose equivalent to 10 LD50 of influenza virus. These peptides corresponded to the following sequences: 23-36 (HA1-1); 138-152 (HA1-3); 183-199 (HA1-6) and 1-11 (HA2-10). Each of the selected peptides, in their free form, evoked anti-peptide antibodies that cross-react with intact X31 virus. Two of the peptides, HA1-1 and HA1-3, also elicited virus-specific delayed type hypersensitivity (DTH) responses. These two peptides, when injected into mice, not only failed to protect the immunized mice against challenge with influenza virus, but in fact caused greater susceptibility to viral infection as compared to control animals that had been injected with saline. In contrast, peptides HA1-6 and HA2-10, which were unable to induce adequate virus-specific DTH responses, conferred 42-46% and 54-73% protection, respectively, compared to the control group that received only saline (P < 0.03 to P < 0.01).
- Published
- 1995
- Full Text
- View/download PDF
32. Evidence that measles virus hemagglutinin initiates modulation of leukocyte function-associated antigen 1 expression.
- Author
-
Nagendra AR, Smith CW, and Wyde PR
- Subjects
- Amino Acid Sequence, Animals, Antibodies, Monoclonal immunology, Cell Aggregation, Cells, Cultured, Chlorocebus aethiops, Hemagglutinins, Viral genetics, Humans, Molecular Sequence Data, Oligopeptides pharmacology, Vero Cells, Hemagglutinins, Viral physiology, Lymphocyte Function-Associated Antigen-1 analysis, Measles virus physiology
- Abstract
Measles virus (MV), human immunodeficiency virus, Epstein-Barr virus, and other leukotropic viruses can modulate the expression of leukocyte function antigen 1 (LFA-1) on the surface of infected and nearby leukocytes. This ability to induce changes in LFA-1 expression may play an important role in the pathogenesis of these viruses. However, the mechanism(s) involved in virus-mediated regulation of LFA-1 is unknown. Evidence is presented in this report that it is the MV hemagglutinin (H) protein that initiates up-regulation of LFA-1 expression in leukocyte cultures infected with this virus. Indeed, comparison of the abilities of different MV strains to modulate LFA-1 expression, examination of published nucleotide sequences for the H proteins of different vaccine strains, and competitive inhibition assays using oligopeptides homologous or heterologous to a region of the H protein gene encompassing amino acid 116 (from the amino terminus) all suggest that it is this portion of the H protein that is responsible for MV-induced alteration of LFA-1. These comparisons also support the hypothesis that there is a relationship between the abilities of different MV strains to alter LFA-1 expression and their pathogenic potentials.
- Published
- 1995
- Full Text
- View/download PDF
33. Evaluation of the antiviral activity of N-(phosphonoacetyl)-L-aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats.
- Author
-
Wyde PR, Moore DK, Pimentel DM, and Blough HA
- Subjects
- Animals, Aspartic Acid pharmacology, Chlorocebus aethiops, Dogs, Evaluation Studies as Topic, Female, Male, Measles virus drug effects, Molecular Structure, Parainfluenza Virus 3, Human drug effects, Phosphonoacetic Acid pharmacology, Rats, Sigmodontinae, Toxicity Tests, Tumor Cells, Cultured, Vero Cells, Antiviral Agents pharmacology, Aspartic Acid analogs & derivatives, Phosphonoacetic Acid analogs & derivatives, Respiratory Syncytial Viruses drug effects, Respirovirus drug effects
- Abstract
N-(phosphonoacetyl)-L-aspartate (PALA), a potent inhibitor of L-aspartic acid transcarbamoylase, was evaluated for cytotoxicity and antiviral activity against three different paramyxoviruses in tissue culture, and for antiviral efficacy and toxicity in vivo using a cotton rat-respiratory syncytial virus (RSV) model. Significant in vitro cytotoxicity was observed in proliferating cultures of HEp-2 (IC50 = 250 micrograms/ml) and Vero cells (IC50 = 32 micrograms/ml), but was less evident in cultures containing confluent monolayers (i.e., stationary cells) of these cells, or in cultures of Madin Darby canine kidney (MDCK) cells (these IC50 values were all > or = 750 micrograms/ml, with 1000 micrograms/ml being the maximum concentration tested). Mean selective indices (ratio of the median cytotoxic dose: median efficacious dose) of 1, 72 and 146 were obtained against parainfluenza virus type 3, RSV and measles virus, respectively, when PALA was tested against these viruses using confluent HEp-2 and Vero cell monolayers. In cotton rats, significant reductions in pulmonary titers (0.8-1.4 log10/g lung) compared to pulmonary viral titers in placebo-treated control animals, were consistently seen in cotton rats given > or = 10 mg of PALA/kg/day (b.i.d.) intraperitoneally on days 1-3 postinfection with either subtype A or B RSV. No toxic effects were noted even in animals given 100 mg of PALA/kg/day for 7 consecutive days.
- Published
- 1995
- Full Text
- View/download PDF
34. A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3.
- Author
-
Du RP, Jackson GE, Wyde PR, Yan WY, Wang Q, Gisonni L, Sanhueza SE, Klein MH, and Ewasyshyn ME
- Subjects
- Amino Acid Sequence, Animals, Antibodies, Monoclonal immunology, Baculoviridae genetics, Base Sequence, Gene Expression, Gene Transfer Techniques, Genetic Engineering, Hemagglutinins chemistry, Hemagglutinins genetics, Hemagglutinins immunology, Molecular Sequence Data, Moths metabolism, Neuraminidase chemistry, Neuraminidase genetics, Neuraminidase immunology, Recombinant Fusion Proteins chemistry, Recombinant Fusion Proteins genetics, Viral Envelope Proteins, Viral Fusion Proteins chemistry, Viral Fusion Proteins genetics, Viral Fusion Proteins immunology, Viral Proteins chemistry, Viral Proteins genetics, Viral Proteins immunology, HN Protein, Parainfluenza Virus 3, Human immunology, Recombinant Fusion Proteins immunology, Respiratory Syncytial Viruses immunology, Vaccines, Synthetic, Viral Vaccines
- Abstract
We have produced a genetically-engineered chimeric protein composed of the external domains of the respiratory syncytial virus (RSV) fusion (F) protein and the parainfluenza virus type 3 (PIV-3) hemagglutinin-neuraminidase (HN) protein in insect cells using the baculovirus expression system. The yield of the soluble chimeric FRSV-HNPIV-3 protein could be increased approximately 2-fold by using Trichoplasia ni (High Five) insect cells in place of Spodoptera frugiperda (Sf9) for expression. The chimeric protein, purified from the supernatant of baculovirus-infected High Five cells by immunoaffinity chromatography was correctly processed at the F2-F1 proteolytic cleavage site. Immunochemical analysis of the chimera with a panel of anti-F and anti-HN monoclonal antibodies suggested that the antigenicity of the major F and HN neutralization epitopes of the chimeric protein was preserved. Immunization of cotton rats with two 1 or 10 micrograms doses of the chimeric protein adsorbed to aluminum phosphate elicited strong PIV-3 specific HAI responses as well as PIV-3 and RSV specific neutralizing antibodies, and at either dose completely protected against challenge with live RSV and PIV-3.
- Published
- 1994
- Full Text
- View/download PDF
35. Infection of leucocytes by measles vaccine viruses Edmonston-Zagreb and Enders-Moraten has different consequences: potential mechanism for increased vaccine efficacy or aberrant activity in field trials.
- Author
-
Wyde PR, Attibele NR, and Kemp WL
- Subjects
- Animals, Antibodies, Viral immunology, Cell Aggregation, Chlorocebus aethiops, Flow Cytometry, Humans, Leukocytes, Mononuclear immunology, Lymphocyte Function-Associated Antigen-1 biosynthesis, Measles Vaccine adverse effects, Measles virus classification, Microbiological Techniques, Neutralization Tests, Vero Cells, Virus Replication, Leukocytes, Mononuclear microbiology, Measles Vaccine immunology, Measles virus immunology
- Abstract
The abilities of two measles vaccine virus strains, Edmonston-Zagreb (E-Z) and Enders-Moraten (E-M), to infect and modify the activities of U937 monocytoid and peripheral blood mononuclear leucocytes (PBMLs) were compared with each other and with changes resulting from infection of these cells by a wild-type measles virus (MV). Both the E-Z and wild-type MV were shown to infect U937 and PBMLs and (1) to markedly increase expression of leucocyte function antigen 1 (LFA-1) on leucocytes present in infected cultures; (2) to increase cell-cell interaction; (3) to grow and disseminate readily in both types of leucocyte cultures; and (4) to persist for more than 7 days in these cultures despite the presence of MV-specific neutralizing antibodies. In contrast, the E-M virus did not grow well in unstimulated PBMLs and, although it did grow well in U937 cells, it did not noticeably alter the expression of LFA-1 on these cells, did not induce significant cell-cell interaction, and was rapidly eliminated from these cultures if MV-specific neutralizing antibodies were present. The possible relationship of these findings to the increased protective efficacy and untoward effects associated with the E-Z MV vaccine is discussed.
- Published
- 1994
- Full Text
- View/download PDF
36. Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice.
- Author
-
Gilbert BE, Wyde PR, Lopez-Berestein G, and Wilson SZ
- Subjects
- Administration, Intranasal, Aerosols, Animals, Candida albicans, Colony Count, Microbial, Disease Models, Animal, Drug Carriers, Female, Kidney microbiology, Liposomes, Male, Mice, Mice, Inbred Strains, Particle Size, Spleen microbiology, Amphotericin B administration & dosage, Amphotericin B pharmacology, Candidiasis drug therapy
- Abstract
Mice lethally infected with Candida albicans were exposed to small-particle aerosols containing amphotericin B-liposomes. The drug, when administered twice daily for 2 h (0.58 mg/kg of body weight per day) on days 1, 2, and 3 postinoculation, significantly reduced the numbers of Candida organisms in the kidneys. Aerosol treatment increased the survival time of mice given 2 2-h treatments once a week for 4 weeks. A twice-weekly, 2-h small-particle aerosol administration of amphotericin B-liposomes for 1, 2, or 3 weeks significantly increased both the mean time of survival and percent survival.
- Published
- 1994
- Full Text
- View/download PDF
37. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon.
- Author
-
Piedra PA, Wyde PR, Castleman WL, Ambrose MW, Jewell AM, Speelman DJ, and Hildreth SW
- Subjects
- Animals, Antibodies, Viral blood, Antibody Formation, Antigens, Viral immunology, Chlorocebus aethiops, Epitopes, Humans, Immunization, Infant, Lung microbiology, Rats, Respiratory Syncytial Virus Infections pathology, Respiratory Syncytial Virus, Human physiology, Sigmodontinae, Vero Cells, Virus Replication drug effects, Formaldehyde adverse effects, Lung drug effects, Lung pathology, Respiratory Syncytial Virus Infections immunology, Respiratory Syncytial Virus, Human immunology, Vaccines, Inactivated adverse effects, Viral Vaccines adverse effects
- Abstract
The specificity of viral antigens in the formalin-inactivated, alum-precipitated respiratory syncytial virus (FI-RSV) vaccine in augmenting the pulmonary inflammatory response was evaluated. Cotton rats were immunized with a FI-RSV vaccine derived from Vero cells, a monkey cell line, or HEp-2 cells, a human cell line. The FI-RSV/Vero and the FI-RSV/HEp-2 vaccines were prepared similarly to the original Lot-100 FI-RSV vaccine that was associated with enhanced disease in the mid-1960s field trials. Each vaccine was administered intramuscularly at various doses and intervals. At 1, 4 or 7 weeks after the last vaccine dose, cotton rats were challenged with 10(6) plaque-forming units of live RSV grown in HEp-2 cells. For controls, FI-parainfluenza, FI-HEp-2 and alum vaccines, and live RSV primary infection were used. For measuring virus replication and histopathology, lungs were harvested at 4 and 8 days postchallenge. A dose-response relationship to vaccine dose was observed for ELISA, neutralizing and antifusion antibodies. All animals given three doses or two of the higher doses of FI-RSV/Vero vaccine developed significant neutralizing antibody, were protected against pulmonary virus replication and had similar low levels of histopathology compared with live RSV and controls. Two immunizations of the lowest dose of FI-RSV/Vero vaccine did not induce neutralizing antibody, did not provide protection of the lung against RSV and did not enhance the pulmonary cellular response. However, FI-RSV/HEp-2 vaccine was associated with significant enhanced pulmonary histopathology despite inducing high titres of neutralizing antibody and protecting the lungs against RSV infection.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1993
- Full Text
- View/download PDF
38. Characterization and administration of cyclosporine liposomes as a small-particle aerosol.
- Author
-
Gilbert BE, Wilson SZ, Garcon NM, Wyde PR, and Knight V
- Subjects
- Aerosols, Animals, Cell Division drug effects, Cyclosporine pharmacokinetics, Cyclosporine pharmacology, Drug Carriers, Liposomes, Lung metabolism, Lymphocytes drug effects, Lymphocytes immunology, Lymphocytes metabolism, Mice, Phosphatidylcholines, Spleen drug effects, T-Lymphocytes drug effects, T-Lymphocytes immunology, T-Lymphocytes metabolism, Thymidine metabolism, Tissue Distribution, Cyclosporine administration & dosage
- Abstract
Systemically administered CsA has not consistently suppressed the pulmonary immunoreactivity that leads to rejection in lung transplant patients. Pulmonary T cells from patients given CsA systemically still retain their immunoreactivity, which can be suppressed with added CsA. Direct application of CsA by aerosol to the respiratory epithelium should achieve high lung concentrations with minimum systemic effects. In the present study, CsA was most efficiently incorporated into liposomes composed of egg yolk phosphatidylcholine at a molar ratio of CsA to egg yolk phosphatidylcholine of 1:20. These CsA liposomes retained their biological activity and were as effective as free CsA in the suppression of anti-CD3-stimulated [3H]thymidine incorporation by mouse spleen cells. The generation of a small-particle aerosol of CsA liposomes had no effect on this biological activity. CsA liposome aerosol particles have a mass median aerodynamic diameter of 2 microns, which allows for distribution of drug throughout the respiratory tract. Quantitation of CsA in the lungs and blood of mice exposed to CsA liposome aerosols for 4 days showed that as little as 15 min daily (0.11 mg/kg/day) was sufficient to achieve an estimated concentration of CsA in respiratory secretions of 6 micrograms/ml without detectable blood levels. Thus, CsA liposomes can be produced and aerosolized that achieve pulmonary concentrations with sufficient immunosuppressive activity to be effective in the treatment of lung diseases.
- Published
- 1993
- Full Text
- View/download PDF
39. Induction of CD8+ cytotoxic T cells by immunization with killed influenza virus and effect of cholera toxin B subunit.
- Author
-
Mbawuike IN and Wyde PR
- Subjects
- Animals, CD4-CD8 Ratio, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes immunology, Cross Reactions, Female, Histocompatibility Antigens Class I immunology, Killer Cells, Natural drug effects, Killer Cells, Natural immunology, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Sensitivity and Specificity, Stimulation, Chemical, CD8 Antigens immunology, Cholera Toxin pharmacology, Immunization, Influenza A virus immunology, Influenza Vaccines pharmacology, Peptide Fragments pharmacology, T-Lymphocytes, Cytotoxic drug effects, T-Lymphocytes, Cytotoxic immunology, Vaccines, Inactivated pharmacology
- Abstract
The MHC class I cytotoxic T-lymphocyte (CTL) response in mice given formalin-inactivated influenza whole-virus vaccine (WVV) with or without cholera toxin B subunit (CTB) was studied. Intraperitoneal injection of Balb/c (H-2d) mice with high doses of A/Taiwan/1/86 (H1N1) WVV stimulated influenza A virus-specific CTL response in a dose-dependent manner. A dose of 4.4 or 44 micrograms induced CTL response equal to or greater than live influenza virus infection. Coadministration of vaccine with 5 or 25 micrograms of CTB resulted in a higher level of CTL than with vaccine alone. CTL lysed A/Taiwan and A/Shanghai (H3N2) virus-infected class I-expressing P815 (H-2d) but not virus-infected EL-4 (H-2b) target cells nor B/Yamagata virus-infected target cells. Virus-infected MHC class II- and class I-expressing A20 (H-2d) targets were also lysed. Depletion of Lyt-2+ (CD8+) T cells with monoclonal antibody completely abrogated lysis of P815 target cells and resulted only in a slight reduction of lysis of A20 target cells. Depletion of L3T4+ (CD4+) T cells or NK cells had minimal effect on lysis of either P815 or A20 target cells. Using limiting dilution analysis, the precursor CTL (pCTL) frequency paralleled CTL activity. Significant CTL activity was detected 7 months after immunization. These results demonstrate that adequate doses of influenza WVV with or without CTB can induce long-lasting influenza A cross-reactive MHC class I-restricted CD8+ CTL response in mice. Thus, coadministration of influenza WVV with CTB may lead to an effective vaccine that stimulates both CTL and antibody responses.
- Published
- 1993
- Full Text
- View/download PDF
40. SP-303 small-particle aerosol treatment of influenza A virus infection in mice and respiratory syncytial virus infection in cotton rats.
- Author
-
Gilbert BE, Wyde PR, Wilson SZ, and Meyerson LR
- Subjects
- Administration, Inhalation, Aerosols, Animals, Antiviral Agents pharmacokinetics, Biopolymers, Catechin pharmacokinetics, Catechin pharmacology, Dose-Response Relationship, Drug, Humans, Influenza, Human microbiology, Mice, Mice, Inbred ICR, Plant Extracts pharmacology, Rats, Respirovirus Infections microbiology, Therapeutic Equivalency, Antiviral Agents pharmacology, Catechin analogs & derivatives, Influenza A virus, Influenza, Human drug therapy, Respiratory Syncytial Viruses, Respirovirus Infections drug therapy
- Abstract
A natural plant product, SP-303, was administered by small-particle aerosol to influenza A/HK virus-infected mice and RSV-infected cotton rats. Aqueous SP-303 at 2 mg/ml in the Collison nebulizer reservoir generated an aerosol with an output of 26 micrograms/l and a particle size distribution of 1.4 microns +/- 4.6 (MMAD +/- GSD). SP-303 at a dosage of 0.5-9.4 mg/kg per day administered for 3-4 days significantly increased both the rate and duration of survival of mice lethally infected with influenza A/HK virus. SP-303 was toxic to mice at 16 mg/kg per day as indicated by weight loss and a decrease in the duration of survival compared to control animals. From these data, a maximum therapeutic index (T.I.) of 12 was calculated. SP-303 given 3-4 days at dosages of 1.3-9.8 mg/kg per day was effective in reducing the pulmonary titer of RSV in infected cotton rats. However, at the 18.7 mg/kg per day dose a significant weight loss compared to control animals was observed; a T.I. of < or = 14 was estimated. These experiments demonstrate that aerosol administration of SP-303 was effective in the treatment of influenza A-infected mice and of RSV-infected cotton rats.
- Published
- 1993
- Full Text
- View/download PDF
41. Measles virus-induced changes in leukocyte function antigen 1 expression and leukocyte aggregation: possible role in measles virus pathogenesis.
- Author
-
Attibele N, Wyde PR, Trial J, Smole SC, Smith CW, and Rossen RD
- Subjects
- Antibodies, Monoclonal pharmacology, CD18 Antigens, Cell Aggregation drug effects, Culture Media pharmacology, Flow Cytometry, Gene Expression Regulation, Humans, Integrins drug effects, Antigens, CD biosynthesis, Leukocytes, Mononuclear microbiology, Lymphocyte Function-Associated Antigen-1 biosynthesis, Measles etiology, Measles virus physiology
- Abstract
Measles virus (MV) infection of U937 cell or peripheral blood leukocyte cultures was shown to induce changes in the expression of leukocyte function antigen 1 (LFA-1) and cause marked aggregation of these cells. Addition of selected monoclonal antibodies specific for LFA-1 epitopes that did not neutralize MV in standard neutralization assays were found to block both virus-induced leukocyte aggregation and virus dissemination. These data suggest that MV modulation of LFA-1 expression on leukocytes may be an important step in MV pathogenesis.
- Published
- 1993
- Full Text
- View/download PDF
42. The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parainfluenza type 3 viruses in cotton rats.
- Author
-
Wyde PR, Ambrose MW, Meyerson LR, and Gilbert BE
- Subjects
- Animals, Antiviral Agents administration & dosage, Body Weight, Catechin pharmacology, Culture Techniques, Lung microbiology, Lung pathology, Paramyxoviridae Infections microbiology, Plants, Medicinal chemistry, Respirovirus Infections microbiology, Ribavirin pharmacology, Sigmodontinae, Viral Plaque Assay, Antiviral Agents therapeutic use, Biopolymers pharmacology, Catechin analogs & derivatives, Parainfluenza Virus 3, Human drug effects, Paramyxoviridae Infections prevention & control, Respiratory Syncytial Viruses drug effects, Respirovirus Infections prevention & control
- Abstract
SP-303, a naturally occurring polyphenolic polymer (average M.W. = 2100 Da), was tested in cotton rats (Sigmoden hispidus) for antiviral activity against respiratory syncytial (RSV) and parainfluenza type 3 (PIV3) viruses, and for acute toxicity. Significant reductions in pulmonary RSV titers, compared to pulmonary RSV titers in comparably treated control animals, were seen in cotton rats given 1-10 mg SP-303/kg/day intraperitoneally (i.p.) on days 1 through to 3, after experimental inoculation with RSV. The minimum efficacious dose of SP-303 against PIV3, when given i.p. for 3 days, was 3 mg/kg/day. Higher doses of SP-303 could not be given i.p., as doses > or = 30 mg/kg/day given once daily by this route for 3 or more consecutive days caused both significant weight loss and death in infected or uninfected animals. Although no toxicity was observed following oral administration of up to 270 mg of SP-303 daily for 3 days, this compound had variable antiviral activity when given by this route.
- Published
- 1993
- Full Text
- View/download PDF
43. Parainfluenza virus type 3 (PIV3)-specific and non-virus-specific delayed type hypersensitivity responses in cotton rats given different PIV3 antigen preparations.
- Author
-
Ambrose MW and Wyde PR
- Subjects
- Animals, Antigens, Viral isolation & purification, Humans, Immunization, Passive, Kinetics, Parainfluenza Virus 3, Human genetics, Parainfluenza Virus 3, Human physiology, Sigmodontinae, Vaccines, Inactivated administration & dosage, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic isolation & purification, Viral Vaccines administration & dosage, Viral Vaccines isolation & purification, Virus Replication, Antigens, Viral administration & dosage, Hypersensitivity, Delayed pathology, Parainfluenza Virus 3, Human immunology
- Abstract
Virus-specific, T-lymphocyte-mediated delayed type hypersensitivity (DTH) responses were studied in cotton rats using replicating (wild-type parainfluenza virus type 3 (PIV3) and recombinant vaccinia virus expressing PIV3 haemagglutinin-neuraminidase (HN) or fusion (F) glycoproteins), and non-replicating (detergent-solubilized, affinity chromatography purified HN and F glycoproteins or inactivated whole PIV3) virus preparations. Significant virus-specific DTH responses were observed in all test groups 1-2 weeks after a single antigen inoculation or 5 days after two inoculations given 3 weeks apart. Peak swelling of ear pinnas in these animals generally occurred 24 h after elicitation and was marked by a cellular infiltration consisting of mono- and polymorphonuclear leucocytes. A considerable non-virus-specific inflammatory response, presumably due to tissue culture or media components in the priming antigen preparations, was observed 3 weeks after priming. No significant differences in DTH responses were observed in cotton rats primed with any of the PIV3 preparations. The possible roles and significance of both the virus-specific and non-virus-specific DTH responses in paramyxovirus-induced disease in humans and cotton rats are discussed.
- Published
- 1993
- Full Text
- View/download PDF
44. Measles virus replication in lungs of hispid cotton rats after intranasal inoculation.
- Author
-
Wyde PR, Ambrose MW, Voss TG, Meyer HL, and Gilbert BE
- Subjects
- Administration, Intranasal, Animals, Antibodies, Viral biosynthesis, Disease Models, Animal, Female, Fluorescent Antibody Technique, Lung pathology, Male, Rats, Time Factors, Virus Replication, Lung microbiology, Measles virus pathogenicity
- Abstract
Hispid cotton rats were inoculated intranasally with either measles virus (MV) Edmonston, a multipassaged, tissue culture-adapted strain of MV, or with one of three clinical MV isolates that had limited passages (three to five times) in tissue culture cells. MV Edmonston was recovered from the lungs of every (n = 37) hispid cotton rat inoculated with this virus for at least 7 days after virus inoculation. Peak pulmonary titers occurred on Day +4 (3.3-4.4 log10/g lung). Scattered areas of inflammation were observed interstitially in lung sections from infected animals stained with hematoxylin and eosin, and a similar pattern of diffuse fluorescence was seen in cryostat sections stained with an indirect fluorescent antibody procedure specific for virus antigens. Fluorescent antibody and virus isolation studies on lung lavage cells both suggested that lung leukocytes were a primary target of the virus. In contrast to these findings, virus was isolated only sporadically from hispid cotton rats inoculated with any of the clinical measles virus isolates. Despite the restricted growth of MV in these animals, cotton rats may be useful for studying certain aspects of measles virus pathogenesis and for screening potential antiviral compounds in vivo.
- Published
- 1992
- Full Text
- View/download PDF
45. Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice.
- Author
-
Gilbert BE, Wyde PR, and Wilson SZ
- Subjects
- Aerosols, Amphotericin B administration & dosage, Animals, Cryptococcosis mortality, Cryptococcus neoformans drug effects, Drug Carriers, Liposomes, Lung Diseases mortality, Mice, Amphotericin B therapeutic use, Cryptococcosis drug therapy, Lung Diseases drug therapy
- Abstract
Cryptococcus infections of the lung and central nervous system have become major problems in immuno-compromised patients, leading to the need for additional treatment protocols. We have utilized a Cryptococcus-mouse model that mimics human cryptococcal disease to evaluate the efficacy of amphotericin B-liposomes (AmpB-Lip) when delivered by small-particle aerosol (SPA). In the model, initial intranasal inoculation leads to a pulmonary infection that spreads after 2 to 3 weeks to distant organs, including the brain. Aerosols of AmpB-Lip that were generated by a Collison nebulizer had mass median aerodynamic diameters of 1.8 microns and contained 10.3 micrograms of AmpB per liter. When AmpB-Lip SPA was begun at 24 h postinoculation, a single 2-h treatment (0.3 mg of AmpB per kg of body weight) was effective in reducing pulmonary Cryptococcus infection. This regimen was more effective than intravenous administration of AmpB-Lip given for 3 continuous days. This single 2-h exposure to AmpB-Lip also was effective in reducing pulmonary Cryptococcus infection when treatment was delayed for 7 or 14 days. At day 21, when organisms had spread to the brain in all animals, the single 2-h aerosol treatment reduced the number of cryptococci in the brain as well as in the lungs. AmpB-Lip SPA administered once for 2 h on days 7, 14, and 21 also was effective in increasing the duration of survival of infected animals. These results demonstrate that aerosolized AmpB-Lip can be effective in treating both local, pulmonary Cryptococcus disease and systemic disease.
- Published
- 1992
- Full Text
- View/download PDF
46. Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats.
- Author
-
Gilbert BE, Wyde PR, Ambrose MW, Wilson SZ, and Knight V
- Subjects
- Aerosols, Animals, Cell Line, Dogs, Drug Administration Schedule, Mice, Sigmodontinae, Time Factors, Influenza A virus drug effects, Orthomyxoviridae Infections drug therapy, Respiratory Syncytial Viruses drug effects, Respirovirus Infections drug therapy, Ribavirin therapeutic use
- Abstract
Ribavirin aerosol administration has been shown to be effective in the treatment of respiratory syncytial virus (RSV) infections in infants and in influenza A and B virus infections in young adults. Long treatment schedules and potential for environmental contamination have stimulated the search for alternative dosing schedules. Thus, we attempted to determine the length of time of ribavirin aerosol necessary for effective treatment of influenza and RSV. In RSV-infected cotton rats, aerosolization for just 30 min with high-dose ribavirin (HDR:60 mg ribavirin/ml in reservoir), 3 times daily, reduced viral lung titers/gm of tissue by 1.1 log10. In influenza virus-infected mice, 15 min of aerosolized HDR, 3 times daily, was effective in reducing both mortality and pulmonary virus titers (1.1 log10 reduction). When the intervals between aerosol administration each day were equally divided (i.e., q.8 h), the treatments were most effective. Treatment for 45 min, once daily, was not as effective as divided doses. Calculations of ribavirin concentrations in respiratory secretions following 15 min treatment in mice with HDR indicated that drug levels dropped below the ED50 for influenza viruses after about 9 h. A daily dosage of ribavirin, estimated to be 8-15 mg/kg, was effective for the treatment of influenza and RSV infections.
- Published
- 1992
- Full Text
- View/download PDF
47. Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus.
- Author
-
Gilbert BE, Wyde PR, Wilson SZ, and Robins RK
- Subjects
- Aerosols, Animals, Brain microbiology, Encephalitis microbiology, Injections, Intraperitoneal, Lung microbiology, Mice, Ribavirin administration & dosage, Ribavirin pharmacokinetics, Encephalitis prevention & control, Influenza A virus, Orthomyxoviridae Infections prevention & control, Ribavirin analogs & derivatives, Ribavirin pharmacology
- Abstract
Ribavirin is active in vitro but not in vivo against a number of viruses capable of causing encephalitis. Ribavirin triacetate (RTA), a lipophilic derivative, has been reported to be more effective than ribavirin in protecting animals from encephalitis. By using an influenza A/WSN virus encephalitis model, we demonstrated that RTA administered by small-particle aerosol was able to decrease the death rate and increase the time of survival. To determine if this beneficial effect was due to increased delivery of drug, the pharmacokinetic properties of ribavirin and RTA when administered as an aerosol or by intraperitoneal injection were examined. Aerosol administration of ribavirin or RTA gave significantly higher concentrations of ribavirin in the lungs and serum of mice than did intraperitoneal injection. There was no difference, however, in ribavirin levels when either ribavirin or RTA was administered by small-particle aerosol. In brain tissue, ribavirin concentrations increased with time and did not appear to decrease as rapidly as in lungs and serum. Mean peak ribavirin concentrations in the brain were higher following aerosol administration of ribavirin than RTA, and both were higher than that following intraperitoneal injection of either drug. Administration of ribavirin or RTA by intraperitoneal injection failed to protect mice from a lethal intracerebral inoculation of influenza A/WSN virus, while aerosolized RTA did protect mice. The pharmacokinetics of ribavirin in brain tissue following aerosol administration of either drug did not explain the advantage of RTA over ribavirin in protecting mice from intracerebral infection with influenza A/WSN virus.
- Published
- 1991
- Full Text
- View/download PDF
48. Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats.
- Author
-
Ambrose MW, Wyde PR, Ewasyshyn M, Bonneau AM, Caplan B, Meyer HL, and Klein M
- Subjects
- Adjuvants, Immunologic, Aluminum immunology, Animals, Cell Line, Female, HN Protein immunology, Hemagglutination Tests, Lung microbiology, Male, Neutralization Tests, Parainfluenza Virus 3, Human isolation & purification, Phosphates immunology, Sigmodontinae, Viral Fusion Proteins immunology, Viral Vaccines administration & dosage, Viral Vaccines adverse effects, Aluminum Compounds, Antibodies, Viral blood, Parainfluenza Virus 3, Human immunology, Paramyxoviridae Infections prevention & control, Viral Vaccines immunology
- Abstract
A parainfluenza virus type 3 (PIV3) subunit vaccine consisting of detergent-solubilized, affinity-purified haemagglutinin-neuraminidase (HN) and fusion (F) surface glycoproteins was tested in cotton rats for immunogenicity, short-term effects on virus-induced immunopathology and protective efficacy. Groups of animals were immunized twice, 4 weeks apart, with graded doses of vaccine administered either alone or with aluminium phosphate (AlPO4). The minimum immunogenic dose of vaccine was 0.1 microgram HN and F when the vaccine was given alone and 0.01 microgram when the vaccine was administered with AlPO4 adjuvant. Antibody responses in animals immunized with 1 microgram HN and F mixed with adjuvant were similar to those in control animals infected with live PIV3 intranasally. Pulmonary and nasal wash PIV3 titres generally were inversely correlated with serum antibody levels. Virus titres were significantly reduced in all groups of animals immunized with greater than or equal to 0.1 microgram HN and F compared with control animals immunized with vehicle only. Four days after virus challenge, there was no evidence of enhanced histopathology in lung sections from animals immunized with the candidate vaccine.
- Published
- 1991
- Full Text
- View/download PDF
49. High dose-short duration ribavirin aerosol treatment--a review.
- Author
-
Knight V, Gilbert BE, Wyde PR, and Englund JA
- Subjects
- Administration, Inhalation, Adolescent, Adult, Aged, Animals, Child, Child, Preschool, Clinical Trials as Topic, Drug Evaluation, Humans, Infant, Infant, Newborn, Mice, Middle Aged, Ribavirin pharmacokinetics, Ribavirin therapeutic use, Influenza A virus, Influenza B virus, Influenza, Human drug therapy, Respiratory Syncytial Viruses, Respirovirus Infections drug therapy, Ribavirin administration & dosage
- Abstract
A high-dose, short-duration treatment with ribavirin aerosol consisting of a three-fold increase in concentration of drug (60 mg versus 20 mg of ribavirin per mL in the liquid reservoir of the generator administered for about one-third the time of the standard treatment) was as effective as the standard dosage in the treatment of experimental influenza A and B infections in mice and in the treatment of experimental respiratory syncytial virus infection in cotton rats. Despite some minor pulmonary intolerance, it was considered to be suitable for use in treatment of patients with severe chronic pulmonary disease, and it was well-tolerated and apparently effective in the treatment (by face mask and endotracheal tube) of infants with bronchiolitis principally caused by respiratory syncytial virus infection. Pharmacokinetic studies in mice revealed very high concentrations of drug in the lungs, about triple the level with the standard dose, with similar blood and brain concentrations. Ribavirin concentrations were similarly high in respiratory secretions of infants given the triple dose.
- Published
- 1991
50. Mutational analysis of regulation of MHC and anti-viral genes.
- Author
-
Rodgers JR, Wyde PR, and Rich RR
- Subjects
- Animals, Kinetics, Mice, Mutation, Phenotype, RNA, Messenger metabolism, Vesicular stomatitis Indiana virus immunology, Cytotoxicity, Immunologic genetics, Interferon-gamma physiology, Major Histocompatibility Complex genetics, T-Lymphocytes, Cytotoxic physiology, Viruses immunology
- Abstract
CTL-mediated selection for loss of expression of Mta by H-2-heterozygous SV40-transformed mouse fibroblasts (line 24SV) produced an unusual phenotypic class of maternally transmitted Ag negative mutants defective in both MHC expression and in anti-viral activity. Severely reduced surface expression of class I MHC Ag from multiple loci of both haplotypes correlated with low levels of MHC H chain and beta 2-microglobulin mRNA. Inasmuch as IFN can up-regulate class I expression and some fibroblasts elaborate autocrine IFN-beta, we examined whether IFN could restore wild-type expression of class I MHC Ag. However, IFN could not restore wild-type expression. Moreover, the fold-increases in class I Ag and mRNA expression were significantly reduced in mutant cells compared to wild-type cells. These results suggested that the mutants might have generalized defects in IFN response. Inasmuch as the induction of an anti-viral state is a hallmark of IFN responses, we exposed cells to IFN-alpha, -beta, or -gamma and challenged with virus. 24SV cells, exposed to any of the three IFNs, were completely protected from destruction by vesicular stomatitis, mengovirus or respiratory syncytial viruses. In contrast, MHC and anti-viral defective mutants could not be protected from virus-induced lysis by any IFN. Somatic cell hybridization analyses indicated that both basal MHC and IFN-inducible phenotypes were recessive to wild-type, and that a trans-acting regulatory factor required for basal MHC expression is defectively expressed in the mutants. Such a factor may integrate the organismal response to virus infection, encompassing both immune and nonimmune anti-viral responses.
- Published
- 1991
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.